Wells Fargo lowered the firm’s price target on Sabra Health Care (SBRA) to $20 from $21 and keeps an Overweight rating on the shares. The firm remains most constructive on Senior Housing as market data continues to signal strength in occupancy and rate, and broker contracts flag accelerated deal volumes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: